Gavia BIO is dedicated to bringing a new antimicrobial peptide (AMP) to market to combat resistant bacterial pathogens at the site of infection.
Antimicrobial resistance (AMR) is considered by the World Health Organization (WHO) as one of the top 10 current and emerging threats for global health. AMR related infections contribute to 1.3 million deaths annually and if not addressed, could lead to 10 million deaths worldwide per year by 2050. To counteract this growing threat, health care teams need new medical tools, protocols and systems including new antibiotics that effectively kill pathogens resistant to the current therapies.
Company Details
- Employees
- 3
- Address
- 266 Mcnamara Alumni Center, Ms 266w,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- Antimicrobial Resistance.
- HQ
- Minneapolis, MN
Gavia Bio, Llc Questions
Gavia Bio, Llc's LinkedIn profile is https://www.linkedin.com/company/gavia-bio
Gavia Bio, Llc has
3 employees.
View email and phone details for 3
employees at Gavia Bio, Llc.
Gavia Bio, Llc's industry is
Biotechnology Research
Gavia Bio, Llc's top competitors are
Heart&core Sports And Medical,
Dolore Biotechnology Llc,
Botech L.l.c.,
Netzro, Sbc,
Kingfisher Biotech,
Carba, Inc.,
Northstar Cryo,
Wavecyte Biolabs,
Flow Environmental Systems,
Syncris.
Gavia Bio, Llc's categories are Biotechnology Research
